US2485501A - Chemotherapeutic agents - Google Patents

Chemotherapeutic agents Download PDF

Info

Publication number
US2485501A
US2485501A US703281A US70328146A US2485501A US 2485501 A US2485501 A US 2485501A US 703281 A US703281 A US 703281A US 70328146 A US70328146 A US 70328146A US 2485501 A US2485501 A US 2485501A
Authority
US
United States
Prior art keywords
tryptophane
chemotherapeutic agents
sulfathiazole
sulfonamide
employed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US703281A
Inventor
Gustav J Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Drug Co
Original Assignee
National Drug Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Drug Co filed Critical National Drug Co
Priority to US703281A priority Critical patent/US2485501A/en
Application granted granted Critical
Publication of US2485501A publication Critical patent/US2485501A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Definitions

  • This invention relates to improved chemotherapeutic agents and more particularly refers to compounds of the sulfonamide group whose activity is markedly increased by employing them in admixture with tryptophane displacers.
  • a further object is to increase the therapeutic activity of sulfonamides whereby substantially smaller amounts thereof may be employed while obtaining the full effectiveness of the customary dosages. Additional objects will become apparent from a consideration of the following description and claim.
  • a further example of the effectiveness of these compositions comprises the treatment of pneumococcic pneumonia in adults.
  • sulfathiazole is frequently used in an initial dose of 4 grams, followed by 1 gram each 4 hours day and night until the patients temperature has been normal for 72 hours. This is a substantial intake of sulfathiazole and frequently produces undesirable toxic effects.
  • the foregoing dosage could be reduced to an initial 0.8 gram of the combination plus 0.2 gram each 4 hours without any noticeable sacrifice in the beneficial effects thereof.
  • the expected undesirable effects of the sulfathiazol can be entirely avoided or substantially minimized. Needless to say this is of tremendous advantage to the patient.
  • sulionamides which may be employed herein are well known and include sulfathiazole,
  • compositions of this invention may be employed either in place of or in admixture with the sulfonamides.
  • chemotherapeutic agents particularly those having a bacteriostatic action, may be employed in the compositions of this invention either in place of or in admixture with the sulfonamides.
  • one or more sulfonamides may be incorporated in these compositions, although as a general rule one of these agents is suflicient.
  • Tryptophane displacers are a well-known group of chemical compounds which have the effect of displacing the amino acid tryptophane when administered. They are represented by the compounds 5-methyl-tryptophane, styrylacrylic acid, styrylacetic acid, thienylalanine, and the ⁇ like Of those displacers I prefer 5-methy1- tryptophane.
  • compositions of my invention are made merely by mixing the sulfonamide and the tryptophane displacer.
  • the mixture may be incorporated in capsules, tablets, etc., in accordance with standard practice.
  • the ratio of sulfonamide to displacer may vary from 1 to 2 or 2 to 1 by weight.
  • amounts of the foregoing agents outside of the preferred range produce desirable results, and it should be understood that the ratio by weight of sulfonamide to displacer may vary from 1 to 10 to 10 to 1, with noticeable improvement on the therapeutic activity of the ingredients.
  • sulfonamides By means of this invention much smaller amounts of sulfonamides may be employed in order to avoid their toxic effects without sacrificing their desirable therapeutic properties.
  • a standard dose of sulfonamide may be employed to give a therapeutic effect approximately ten times that of this agent alone by combining it with a, tryptophane displacer as aforesaid.
  • a synergistic composition comprising from 1 to 10 parts by weight of sulfathiazole and from 10 to 1 parts by weight of 5-methyl-tryptophane.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented Oct. 18, 1949 CHEMOTHERAPEUTIC AGENTS Gustav J. Martin, Philadelphia, Pa., assignor to The National Drug Company, Philadelphia, Pa., a corporation of Pennsylvania No Drawing. Application October 15, 1946, Serial No. 703,281
1 Claim. 1
This invention relates to improved chemotherapeutic agents and more particularly refers to compounds of the sulfonamide group whose activity is markedly increased by employing them in admixture with tryptophane displacers.
It is an object of this invention to produce new chemotherapeutic agents having superior therapeutic activity. A further object is to increase the therapeutic activity of sulfonamides whereby substantially smaller amounts thereof may be employed while obtaining the full effectiveness of the customary dosages. Additional objects will become apparent from a consideration of the following description and claim.
In accordance with this invention I have found that when a member of the well-known class of tryptophane displacers is mixed with a member of the sulfonamide group, the resulting composition is synergistic in that it possesses a chemotherapeutic activity which is substantially greater than the sum total of the activity of the two ingredients. For example, 1 M. E. C. (min imum effective concentration) of sulfathiazole has by definition the same antibacterial power as 1 M. E. C. of 5-methyl-tryptophane. By mixing 0.1 M. E. C. of sulfathiazole with 0.1 M. E. C. of B-methyl-tryptophane I have found that the same antibacterial action is obtained as though 1 M. E. C. of either agent had been employed. This means that the same chemotherapeutic effect could be obtained using 0.1 the dosage of either compound. Since the toxicity of the sulfonamides is generally recognized and presents a serious problem in their use, this invention permits the desirable results of these compounds to be obtained while markedly minimizing their undesirable efiects. My compositions evidence improved effectiveness for either internal or external use.
A further example of the effectiveness of these compositions comprises the treatment of pneumococcic pneumonia in adults. For the treatment of this condition sulfathiazole is frequently used in an initial dose of 4 grams, followed by 1 gram each 4 hours day and night until the patients temperature has been normal for 72 hours. This is a substantial intake of sulfathiazole and frequently produces undesirable toxic effects. By employing a mixture containing equal amounts of sulfathiazole and S-methyltryptophane, the foregoing dosage could be reduced to an initial 0.8 gram of the combination plus 0.2 gram each 4 hours without any noticeable sacrifice in the beneficial effects thereof. As a result, the expected undesirable effects of the sulfathiazol can be entirely avoided or substantially minimized. Needless to say this is of tremendous advantage to the patient.
The sulionamides which may be employed herein are well known and include sulfathiazole,
2 sulfadiazine, sulfanilamide, sulfapyridine, and the like. It is also contemplated that other chemotherapeutic agents, particularly those having a bacteriostatic action, may be employed in the compositions of this invention either in place of or in admixture with the sulfonamides. Likewise it is contemplated that one or more sulfonamides may be incorporated in these compositions, although as a general rule one of these agents is suflicient.
Tryptophane displacers are a well-known group of chemical compounds which have the effect of displacing the amino acid tryptophane when administered. They are represented by the compounds 5-methyl-tryptophane, styrylacrylic acid, styrylacetic acid, thienylalanine, and the {like Of those displacers I prefer 5-methy1- tryptophane.
The compositions of my invention are made merely by mixing the sulfonamide and the tryptophane displacer. The mixture may be incorporated in capsules, tablets, etc., in accordance with standard practice. For optimum results I prefer to use 1 part by weight of the sulfonamide to an amount of tryptophane displacer within the range of /2 to 2 parts by weight. In other words, the ratio of sulfonamide to displacer may vary from 1 to 2 or 2 to 1 by weight. I have found that amounts of the foregoing agents outside of the preferred range produce desirable results, and it should be understood that the ratio by weight of sulfonamide to displacer may vary from 1 to 10 to 10 to 1, with noticeable improvement on the therapeutic activity of the ingredients.
By means of this invention much smaller amounts of sulfonamides may be employed in order to avoid their toxic effects without sacrificing their desirable therapeutic properties. In the same manner, a standard dose of sulfonamide may be employed to give a therapeutic effect approximately ten times that of this agent alone by combining it with a, tryptophane displacer as aforesaid.
As many apparently widely different embodiments of this invention maybe made without departing from the spirit and scope hereof, it is to be understood that the invention is not limited tothe specific embodiments hereof except as defined in the appended claim.
I claim:
A synergistic composition comprising from 1 to 10 parts by weight of sulfathiazole and from 10 to 1 parts by weight of 5-methyl-tryptophane.
GUSTAV J. MARTIN.
REFERENCES CITED The following references are of record in the file of this patent:
Anderson in Science, June 1, 1945, pages 565 and 566. (Copy in Patent Office Scientific Library.)
US703281A 1946-10-15 1946-10-15 Chemotherapeutic agents Expired - Lifetime US2485501A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US703281A US2485501A (en) 1946-10-15 1946-10-15 Chemotherapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US703281A US2485501A (en) 1946-10-15 1946-10-15 Chemotherapeutic agents

Publications (1)

Publication Number Publication Date
US2485501A true US2485501A (en) 1949-10-18

Family

ID=24824762

Family Applications (1)

Application Number Title Priority Date Filing Date
US703281A Expired - Lifetime US2485501A (en) 1946-10-15 1946-10-15 Chemotherapeutic agents

Country Status (1)

Country Link
US (1) US2485501A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Similar Documents

Publication Publication Date Title
US2283817A (en) Detoxicant
ES346635A1 (en) Process for the preparation of 2-phenylamino-1,3-diazacycloalkenes-2
US2485501A (en) Chemotherapeutic agents
US2550489A (en) Ulcer therapy composition
US3197370A (en) Pyrilamine tannate compositions
US2416236A (en) Series of nitrofuran compounds
US2342879A (en) Detoxicant
US2027722A (en) Therapeutic agent
US3085932A (en) Therapeutic composition comprising 3, 3-diethyl-5-methyl-2, 4-piperidinedione and 7-chloro-2-methylamino-5-phenyl-3h-1, 4-benzodiazepine-4-oxide
US2376795A (en) Sulphapyridine composition of low toxicity
US2366742A (en) Detoxicant
US1845486A (en) Synergized codein drugs
US2484175A (en) Therapeutic sulfonamide compositions
US2981657A (en) Thyroprotein and strophanthin composition for reducing body weight
Wilkinson et al. Treatment of leukaemias and reticuloses with uracil mustard
ES269442A1 (en) Lysine orotate
US3067242A (en) Di-(n, n-dimethyloctadecylamine) pamoate
US2498200A (en) Stabilized thiamin
US2363541A (en) Detoxicant
US2748052A (en) Therapeutically active compositions containing amphetamine
US3323991A (en) Synergistic coccidiostatic compositions and methods
US1716686A (en) Pharmaceutical
SULTAN et al. Sulfonamide compounds and penicillin: the effect of combined therapy on experimental infections in mice
US3519712A (en) Therapeutic compositions comprising n-methylglucamine and coumermycin or salts thereof
US3138529A (en) Tetracycline antibiotic compositions for oral use